Summary: In a small mechanistic study in adults with type 2 diabetes, acute exenatide plus glucagon co-infusion roughly doubled myocardial glucose uptake and improved a marker of diastolic function compared with saline, offering proof-of-concept that the diabetic heart’s metabolic inflexibility can be pharmacologically shifted.
PICO Summary
| Element | Detail |
|---|---|
| Population | 8 adults with type 2 diabetes (mean age 52, BMI 31); three randomised infusion visits with FDG PET-MRI. |
| Intervention | Exenatide:glucagon co-infusion (exenatide 50 ng/min load then 25 ng/min; glucagon 12.5 ng/kg/min). |
| Comparison | 0.9% saline or glucagon alone. |
| Outcome | Myocardial glucose uptake rose in 7/8 from a median 9.2 to 20 ×10⁻³ µmol/g/min (p<0.05). Left-ventricular peak diastolic circumferential strain rate improved (p<0.05). Global longitudinal strain change non-significant (p=0.12). |
Exenatide + glucagon co-infusion in type 2 diabetes
Crossover RCT · type 2 diabetes · acute infusion
Acute exenatide plus glucagon co-infusion roughly doubled myocardial glucose uptake versus saline and improved a diastolic strain marker, a proof-of-concept that the diabetic heart's substrate inflexibility can be pharmacologically shifted.
Expert Commentary
This is laboratory physiology, not a clinical trial, and on those terms it is an elegant little study. The diabetic heart’s reliance on fatty-acid oxidation and its loss of substrate flexibility is a credible contributor to diabetic cardiomyopathy, and showing that a GLP-1/glucagon co-infusion can acutely double myocardial glucose uptake and nudge a diastolic strain marker gives a plausible mechanistic thread for the cardiovascular benefits the GLP-1 class shows in large outcome trials. My discipline here is to keep it firmly in its lane. Eight patients, an acute intravenous infusion that bears no resemblance to chronic subcutaneous dosing, surrogate imaging endpoints, and a combination that exists as no actual product, all mean this generates hypotheses rather than guiding care. The longitudinal-strain measure did not even reach significance. Can I use this with my patients? No, not directly. It adds mechanistic comfort to a decision I already make on outcome-trial evidence, prioritising GLP-1 agonists in diabetic patients at cardiac risk, and it makes the emerging dual GLP-1/glucagon agonists interesting to watch. I would want chronic-dosing studies with real cardiac endpoints before drawing anything clinical.
References
Goodman J, Schain M, Di Stefano G, et al. Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes. Sci Rep. 2025;15(1):21404. doi:10.1038/s41598-025-04559-3